Would you consider the use of ctDNA as part of surveillance in high risk TNBC patients?
In patients who have completed all adjuvant therapy. Similar test to what is available for stage 2 and 3 colon cancer patients by Natera.
Answer from: Medical Oncologist at Academic Institution
Patients with significant residual TNBC following NAC have an increased risk of recurrence and death within 3 years, despite SOC adjuvant capecitabine (EA1131). The presence of ctDNA following initial active treatment (using Signatera or other platforms) has reliably shown to predict risk of recurre...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I would not recommend unless part of a clinical trial as we do not know what to do with the information. We all recall how randomized trials using tumor markers and surveillance scans did not impact outcome, unclear how this is truly different.